Get my own profile
Public access
View all10 articles
0 articles
available
not available
Based on funding mandates
Co-authors
- Gavin GiovannoniBarts and The London School of Medicine and DentistryVerified email at giovannoni.net
- Michel GoedertMRC Laboratory of Molecular Biology, Cambridge, UKVerified email at mrc-lmb.cam.ac.uk
- Michael O'NeillHead of Molecular Pathology, Eli Lilly & Co. Ltd.Verified email at lilly.com
- Annalisa CavalliniEli Lilly and Co.Ltd.Verified email at lilly.com
- Philip SzekeresAstraZeneca, Eli Lilly, GlaxoSmithKline, Cambridge, LoughboroughVerified email at lilly.com
- Benjamin Ryskeldi-FalconGroup Leader, MRC Laboratory of Molecular Biology (LMB)Verified email at mrc-lmb.cam.ac.uk
- Adrian IsaacsUCL Institute of NeurologyVerified email at ucl.ac.uk
- Jennifer PocockInstitute of Neurology, University College London (UCL)Verified email at ucl.ac.uk
- Axel PetzoldUniversity College London, The National Hospital for Neurology and Neurosurgery & Moorfields EyeVerified email at ucl.ac.uk
- Ilaria BellantuonoProfessor in Musculoskeletal AgeingVerified email at sheffield.ac.uk
- Mark YeomanUniversity of BrightonVerified email at brighton.ac.uk
- Hugo M. VargasExecutive Director, Translational Safety & Pharmacology, Amgen, IncVerified email at amgen.com
- Andy MeadAstraZenecaVerified email at astrazeneca.com